ZWS Stock Forecast & Price Target

Zurn Elkay Water Solns is compelling because it combines defensively positioned end markets with strong execution, as education and healthcare represent 80% of institutional sales and roughly 39% of total sales, supporting resilient demand through cycles. The company’s outlook is further strengthened by 3Q26 organic sales growth of 7%, adjusted EBITDA margins of 28.3% that expanded 150 bps year over year, and free cash flow conversion of 126%, evidence of durable pricing power and operating discipline. Management’s raised incremental EBITDA margin target to above 40%, 0.4x net leverage, $307 million of cash, and successful expansion into a roughly $400 million served-market opportunity reinforce its ability to fund growth, M&A, buybacks, and dividends while compounding shareholder value.

Zurn Elkay Water Solns is viewed negatively because its premium valuation already reflects strong positioning, leaving limited upside if growth slows or the stock merely re-rates toward peers. A material deceleration in institutional and commercial construction, deferred education and healthcare budgets, or share loss versus major competitors could pressure volumes, mix, and the company’s premium multiple. In addition, execution risk around M&A, supply-chain volatility in copper, brass, steel, plastics, and electronics, and slower adoption of higher-margin touchless/IoT products could constrain margins and make 2027 EPS of about $1.89 harder to achieve.